word
count
model
viral
dynam
untreat
patient
infect
infer
viral
growth
paramet
predict
effect
antivir
treatment
order
reduc
peak
viral
load
log
drug
efficaci
need
greater
treatment
administ
symptom
onset
efficaci
could
suffici
treatment
initi
symptom
onset
given
pharmacokineticpharmacodynam
properti
current
investig
drug
may
rang
efficaci
may
help
control
viru
administ
earli
may
major
effect
sever
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
model
viral
dynam
untreat
patient
infect
infer
viral
growth
paramet
predict
effect
antivir
treatment
order
reduc
peak
viral
load
log
drug
efficaci
need
greater
treatment
administ
symptom
onset
efficaci
could
suffici
treatment
initi
symptom
onset
given
pharmacokineticpharmacodynam
properti
current
investig
drug
may
rang
efficaci
may
help
control
viru
administ
earli
may
major
effect
sever
patient
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
outbreak
sever
acut
respiratori
syndrom
coronaviru
origin
wuhan
china
becom
global
pandem
march
viru
infect
peopl
worldwid
caus
death
despit
unpreced
mobil
clinic
scientif
commun
develop
larg
scale
implement
new
antivir
drug
vaccin
take
month
readili
propos
first
line
defens
combat
viru
hospit
patient
world
health
organ
reli
alreadi
exist
drug
repurpos
immedi
avail
larg
quantiti
good
safeti
profil
coordin
european
institut
franc
implement
random
clinic
trial
hospit
patient
discoveri
compar
efficaci
lopinavirritonavir
remdesivir
hydroxychloroquin
given
limit
knowledg
hostpathogen
interact
clinic
efficaci
treatment
strategi
use
drug
larg
unknown
could
limit
fit
mathemat
model
viral
dynam
vivo
data
provid
estim
paramet
drive
viral
replic
model
use
predict
need
efficaci
treatment
optim
use
combin
predict
expect
drug
concentr
ec
drug
candid
one
anticip
effect
variou
dose
regimen
dose
time
treatment
initi
viral
load
dynam
data
use
fit
use
publish
data
untreat
patient
infect
follow
singapor
hospit
patient
hospit
median
day
onset
symptom
rang
median
symptomat
period
day
rang
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
viral
load
nasopharyng
swab
measur
real
time
revers
transcriptas
polymeras
chain
reaction
rt
pcr
lower
limit
quantif
cycl
ct
multipl
time
point
observ
peak
viral
load
day
post
onset
symptom
rang
day
data
present
ct
transform
copiesml
use
publish
relationship
zou
et
al
model
fit
viral
load
note
transform
ct
log
copiesml
affect
estim
paramet
interest
particular
r
death
rate
product
infect
cell
time
sinc
infect
assum
day
onset
symptom
sensit
analysi
also
examin
valu
day
model
viral
dynam
fit
use
target
cell
limit
model
eclips
phase
model
consid
three
popul
cell
target
cell
infect
cell
eclips
phase
product
infect
cell
given
timescal
infect
neglect
target
cell
prolifer
natur
death
focus
process
cell
deplet
viru
infect
assum
target
cell
becom
infect
rate
constant
averag
time
cell
start
produc
viru
clear
per
capita
rate
virion
releas
product
infect
cell
rate
p
per
cell
clear
circul
per
capita
rate
c
base
model
basic
reproduct
number
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
assum
target
cell
concentr
cellsml
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
absenc
treatment
ie
day
symptom
onset
model
provid
best
descript
data
use
simul
sensit
analys
conduct
evalu
result
obtain
differ
assumpt
regard
delay
time
infect
time
symptom
onset
either
day
supplement
inform
fig
reli
literatur
find
pk
popul
paramet
lopinavirritonavir
hydroxychloroquin
well
report
ec
valu
vitro
see
tabl
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
use
targetcel
limit
model
eclips
phase
fig
tabl
influenza
anoth
respiratori
infecti
diseas
estim
within
host
r
vari
greatli
halflif
infect
cell
shorter
hour
see
detail
suggest
faster
clearanc
influenza
infect
cell
number
also
inform
us
time
initi
antivir
treatment
level
efficaci
need
achiev
reduc
viral
load
limit
inform
avail
mechan
lead
viral
clearanc
may
modul
treatment
use
model
predict
effect
treatment
day
post
symptom
correspond
time
viral
load
tend
peak
absenc
treatment
consid
simpl
case
drug
effect
assum
constant
therapi
initi
see
method
calcul
minim
efficaci
would
need
gener
log
viral
declin
peak
viral
load
studi
patient
fig
predict
viral
kinet
model
theori
found
impact
treatment
peak
viral
load
invers
correl
time
treatment
initi
put
treatment
initi
time
infect
symptom
onset
day
post
symptom
onset
median
efficaci
least
reduc
viral
replic
would
need
respect
gener
log
declin
peak
viral
load
fig
authorfund
grant
medrxiv
licens
display
preprint
perpetu
mean
antivir
effect
first
day
treatment
given
given
pharmacokinet
pharmacodynam
properti
tabl
calcul
mean
antivir
efficaci
lopinavirritonavir
hydroxychloroquin
given
estim
compound
unlik
dramat
effect
peak
viral
load
administ
onset
symptom
fact
effect
concentr
presum
lower
patient
relev
drug
may
limit
protein
bind
particular
lopinavir
protein
bind
rate
capabl
penetr
respiratori
compart
well
character
importantli
level
antivir
efficaci
could
nonetheless
relev
prophylact
set
symptom
onset
reduc
viral
replic
upper
respiratori
tract
reduc
risk
larg
infiltr
lung
effect
immun
respons
mount
clear
viru
note
calcul
effect
drug
administ
monotherapi
usual
dose
regimen
also
consid
drug
could
directli
target
infect
cell
lead
elimin
monoclon
antibodi
overal
result
emphas
pkpd
properti
lopinavirritonavir
hydroxychloroquin
make
unlik
dramat
impact
viral
load
kinet
nasopharynx
administ
symptom
onset
given
possibl
continu
viral
replic
presenc
drug
select
drug
resist
mutat
seen
rna
virus
although
coronavirus
unusu
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
appear
low
mutat
rate
due
rna
proofread
capabl
drug
combin
therapi
aggress
dose
includ
consider
load
dose
rapidli
achiev
therapeut
exposur
may
benefici
maxim
efficaci
repurpos
antivir
agent
howev
may
relev
preor
postexposur
prophylaxi
administr
reduc
viral
replic
henc
risk
diseas
progress
